Abstract |
Fragile X syndrome (FXS) is the leading cause of both intellectual disability and autism resulting from a single gene mutation. Previously, we characterized cognitive impairments and brain structural defects in a Drosophila model of FXS and demonstrated that these impairments were rescued by treatment with metabotropic glutamate receptor (mGluR) antagonists or lithium. A well-documented biochemical defect observed in fly and mouse FXS models and FXS patients is low cAMP levels. cAMP levels can be regulated by mGluR signaling. Herein, we demonstrate PDE-4 inhibition as a therapeutic strategy to ameliorate memory impairments and brain structural defects in the Drosophila model of fragile X. Furthermore, we examine the effects of PDE-4 inhibition by pharmacologic treatment in the fragile X mouse model. We demonstrate that acute inhibition of PDE-4 by pharmacologic treatment in hippocampal slices rescues the enhanced mGluR-dependent LTD phenotype observed in FXS mice. Additionally, we find that chronic treatment of FXS model mice, in adulthood, also restores the level of mGluR-dependent LTD to that observed in wild-type animals. Translating the findings of successful pharmacologic intervention from the Drosophila model into the mouse model of FXS is an important advance, in that this identifies and validates PDE-4 inhibition as potential therapeutic intervention for the treatment of individuals afflicted with FXS.
|
Authors | Catherine H Choi, Brian P Schoenfeld, Eliana D Weisz, Aaron J Bell, Daniel B Chambers, Joseph Hinchey, Richard J Choi, Paul Hinchey, Maria Kollaros, Michael J Gertner, Neal J Ferrick, Allison M Terlizzi, Nicole Yohn, Eric Koenigsberg, David A Liebelt, R Suzanne Zukin, Newton H Woo, Michael R Tranfaglia, Natalia Louneva, Steven E Arnold, Steven J Siegel, Francois V Bolduc, Thomas V McDonald, Thomas A Jongens, Sean M J McBride |
Journal | The Journal of neuroscience : the official journal of the Society for Neuroscience
(J Neurosci)
Vol. 35
Issue 1
Pg. 396-408
(Jan 07 2015)
ISSN: 1529-2401 [Electronic] United States |
PMID | 25568131
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.)
|
Copyright | Copyright © 2015 the authors 0270-6474/15/350396-13$15.00/0. |
Chemical References |
- Phosphodiesterase 4 Inhibitors
- Cyclic Nucleotide Phosphodiesterases, Type 4
|
Topics |
- Animals
- Animals, Genetically Modified
- Cyclic Nucleotide Phosphodiesterases, Type 4
(genetics, metabolism)
- Disease Models, Animal
- Drosophila
- Female
- Fragile X Syndrome
(drug therapy, enzymology, genetics)
- Male
- Mice
- Mice, Knockout
- Neuronal Plasticity
(drug effects, physiology)
- Phosphodiesterase 4 Inhibitors
(pharmacology, therapeutic use)
|